I write Exits & Outcomes: members-only digital health newsletters + research reports. @ExitsOutcomes Before: Founder, MobiHealthNews (acq'd) Tip? DM for Signal.
Massachusetts
Joined October 2008
- Tweets5.1K
- Following4.2K
- Followers25.7K
- Likes2.1K
Brian Dolan retweeted
can't recommend @bddol 's exit & outcomes publication enough - the databases alone are interesting
exitsandoutcomes.com/pricing…
Brian Dolan retweeted
Now you’re just straight up stealing all my best client advice. Including that they need to subscribe to @ExitsOutcomes
Brian Dolan retweeted
Love @ExitsOutcomes. Among the best healthcare analysts around.
The SWORD Health Report is yet another banger by @ExitsOutcomes
My fav insight: don't try and sell to the big boyz from day 1
Almost never works. Instead target small customers, get their feedback, and use them for your marketing
Brian Dolan retweeted
Won't spill all the beans, but you can find the complete report here: exitsandoutcomes.com/the-spr…
(don't forget to subscribe to @bddol's blog)
Brian Dolan retweeted
The Spring Health Report is another banger by @ExitsOutcomes (@bddol). My top three favorite insights:
(1) Sell then build
Doesn't matter if this is your 1st product or a feature you'll spend significant time on. Make sure people want to pay (extra)
Quite the turn of events: I speculated last week that the mystery buyer of Pear Therapeutics' core assets was its ex-CEO. The purchase agreement reveals this to be true. McCann, under the name Harvest Bio, seems intent on resurrecting Pear using the following assets --> (1/3)
The judge presiding over the bankruptcy court proceedings still needs to sign off on the asset sales --so this isn't a done deal yet. And some have already objected to the sale to McCann -- including the federal government and the South Carolina Department of Corrections. (3/3)
In this week's @ExitsOutcomes Friday newsletter:
- Was ex-CEO the mystery buyer in Pear's asset auction?
- Woebot pauses its postpartum depression prescription digital therapeutic
-Swing Therapeutics gets FDA De Novo but PDT go-to-market is its own virtual clinic, Swing Care
Brian Dolan retweeted
This report from @bddol on @wearebighealth is a must read for everyone interested in the Dtx space
The most interesting part to me was that Big Health uses its clinical research programs as a moat - see a slide of their sales deck (2021):
Brian Dolan retweeted
excellent thread - and I think your point around digital therapeutics building out full clinics is already happening (see below h/t @bddol)
IMO the path forward is to build out opinionated care models that target a specific disease area, which I think dTX can be great for
Brian Dolan retweeted
Pear Therapeutics announced that they are filing for bankruptcy, which made me sad. Although my thinking has changed over time on DTx, I am still a fanboy at heart, feel pretty lucky to have seen this whole arc and feel like reminiscing. forbes.com/sites/katiejennin…
Which health tech-focused (entirely or partially) investors/VCs have worthwhile newsletters, podcasts, or blogs that are more under-the-radar than others?
No surprise here: Pear Therapeutics is looking for a buyer. The company isn't going to hold a Q4/FY22 investor call anymore. Pear was the first prescription digital therapeutics company to go public via SPAC.
A few weeks ago when Pear's chief commercial officer departed and its stock dropped below $1 for the first time, I wondered if we'd see a buyer step up soon (Exits & Outcomes Issue 184):
Brian Dolan retweeted
i think this approach makes a lot more sense from a payment and value capture perspective. and for controlling the experience and making sure the DTx tools are used uniformly and effectively.
Brian Dolan retweeted
pretty interesting via @bddol - a digital therapeutics company spinning out a virtual clinic
I suspect as more digital therapeutics struggle to get payer + clinician adoption, this becomes a more popular go-to-market especially to get evidence
Breaking news in AliveCor-Apple suits: ITC decided to ban importation of Apple Watch bc it infringes AliveCor patents. But: Because Apple just won a case in the USPTO/PTAB court... this ITC decision won't be enforced until the PTAB case goes through appeals process (1/2)
Apple + healthcare provider partners + half a dozen supporters in Congress tried to convince the ITC that the public interest was better served by not banning import of Apple Watches bc they were used in so many health studies and programs. The ITC wasn't swayed by that.
